Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 12/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
| ▸ | CPT1A | P50416 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12570206 | 1.00 | RORC (0.46) | RORCCNR1CNR2CPT1AMEN1 | |
| SCHEMBL2002936 | 1.00 | RORC (0.46) | RORCCNR1CNR2CPT1AMEN1 | |
| SCHEMBL13669916 | 1.00 | RORC (0.46) | RORCCNR1CNR2CPT1AMEN1 | |
| SCHEMBL12570237 | 1.00 | RORC (0.46) | RORCCNR1CNR2CPT1AMEN1 | |
| SCHEMBL2006856 | 1.00 | RORC (0.46) | RORCCNR1CNR2CPT1AMEN1 | |
| SCHEMBL2001170 | 0.98 | RORC (0.46) | RORCCNR1CNR2CPT1AKMT2A | |
| SCHEMBL13670208 | 0.98 | RORC (0.46) | RORCCNR1CNR2CPT1AKMT2A | |
| SCHEMBL2001759 | 0.90 | RORC (0.49) | RORCCNR1CNR2CPT1AMEN1 | |
| SCHEMBL2000254 | 0.86 | RORC (0.47) | RORCCNR1CNR2CPT1AMEN1 | |
| SCHEMBL2000252 | 0.86 | RORC (0.47) | RORCCNR1CNR2CPT1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | claimed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CNR1, CNR2, TRPV1 | RORC 122/4885CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.